Discontinue use if progressive multifocal leukoencephalopathy is confirmed; serious opportunistic or recurrent infections develops in patients w/ low Ig; prolonged hypogammaglobulinemia requiring treatment w/ IVIg; hypersensitivity or life-threatening systemic inj-related reaction occurs. Not to be inj into moles, scars, stretch marks, tender, bruised, red, scaly or hard skin. Serious, including life-threatening or fatal, bacterial, fungal & new or reactivated viral infections; HBV reactivation & infection; local inj-related reactions. Perform HBV screening including HBsAg, hepatitis B core Ab & quantitative serum Ig prior to therapy. Immunogenicity. Not recommended w/ live or live-attenuated vaccines. Concomitant use w/ immunosuppressive therapy. Women of childbearing potential should use effective contraception during & at least 6 mth after last dose. Pregnancy & lactation. Ped.
Sign Out
